Notably, this aligns with the innovative approach reported by Jiao et al (8), where a combination of lapatinib, trastuzumab, and capecitabine provided rapid symptomatic relief in a HER2-positive gastric cancer patient with LM-GC. The gene discussed is ERBB2; the disease is gastric cancer.